Kubo, A <br/><br/>
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Dec 1999 
 - 4279-86 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Cyclin-Dependent Kinase 4<br/>Cyclin-Dependent Kinase Inhibitor p16--deficiency<br/>Cyclin-Dependent Kinases--antagonists & inhibitors<br/>Drug Screening Assays, Antitumor<br/>Enzyme Inhibitors--pharmacology<br/>Genes, p16<br/>Growth Inhibitors--pharmacology<br/>Humans<br/>Polymerase Chain Reaction<br/>Polymorphism, Single-Stranded Conformational<br/>Proto-Oncogene Proteins<br/>Structure-Activity Relationship<br/>Substrate Specificity<br/>Tumor Cells, Cultured